Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension

New England Journal of Medicine

Volumn 338, Issue 5, 1998, Pages 273-277

  McLaughlin, Vallerie V ^a   Genthner, Diane E ^a   Panella, Maureen M ^a   Rich, Stuart ^a,b  

^a RUSH MEDICAL COLLEGE   (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE; PROSTACYCLIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; EXERCISE; FEMALE; FLUSHING; HEADACHE; HEMODYNAMICS; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG VASCULAR RESISTANCE; MALE; MAXIMUM PERMISSIBLE DOSE; PAIN; PRIORITY JOURNAL; PULMONARY HYPERTENSION; VASODILATATION;

ADULT; ANTIHYPERTENSIVE AGENTS; EPOPROSTENOL; FEMALE; FOLLOW-UP STUDIES; HEMODYNAMIC PROCESSES; HUMANS; HYPERTENSION, PULMONARY; INFUSIONS, INTRAVENOUS; MALE; PULMONARY ARTERY; VASCULAR RESISTANCE;

EID: 0032576672     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199801293380501     Document Type: Article

References (17)

1. Fuster V, Steele PM, Edwards WD, Gersh BJ, McGoon MD, Frye RL. Primary pulmonary hypertension: natural history and the importance of thrombosis. Circulation 1984;70:580-7.
2. Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992;327:76-81.
3. Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med 1996;334:296-301.
4. Vane JR, Botting RM. Pharmacodynamic profile of prostacyclin. Am J Cardiol 1995;75:3A-10A.
5. Barst RJ. Pharmacologically induced pulmonary vasodilatation in children and young adults with primary pulmonary hypertension. Chest 1986; 89:497-503.
6. Weir EK, Rubin LJ, Ayres SM, et al. The acute administration of vasodilators in primary pulmonary hypertension: experience from the National Institutes of Health Registry on Primary Pulmonary Hypertension. Am Rev Respir Dis 1989;140:1623-30.
7. Barst RJ, Rubin LJ, McGoon MD, Caldwell EJ, Long WA, Levy PS. Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin. Ann Intern Med 1994;121:409-15.
8. Rich S, Dantzker DR, Ayres SM, et al. Primary pulmonary hypertension: a national prospective study. Ann Intern Med 1987;107:216-23.
9. Nootens M, Schrader B, Kaufmann E, Vestal R, Long W, Rich S. Comparative acute effects of adenosine and prostacyclin in primary pulmonary hypertension. Chest 1995;107:54-7.
10. Wagenvoort CA, Wagenvoort N. Primary pulmonary hypertension: a pathologic study of the lung vessels in 156 clinically diagnosed cases. Circulation 1970;42:1163-84.
11. Pietra GG, Edwards WD, Kay JM, et al. Histopathology of primary pulmonary hypertension: a qualitative and quantitative study of pulmonary blood vessels from 58 patients in the National Heart, Lung, and Blood Institute, Primary Pulmonary Hypertension Registry. Circulation 1989;80: 1198-206.
12. Wagenvoort CA. Hypertensive pulmonary vascular disease: the point of no return. Minn Med 1985;68:45-8.
13. Rich S, Brundage BH. High-dose calcium channel-blocking therapy for primary pulmonary hypertension: evidence for long-term reduction in pulmonary arterial pressure and regression of right ventricular hypertrophy. Circulation 1987;76:135-41.
14. Rubin LJ, Nicod P, Hillis LD, Firth BG. Treatment of primary pulmonary hypertension with nifedipine: a hemodynamic and scintigraphic evaluation. Ann Intern Med 1983;99:433-8.
15. Higenbottam TW, Wheeldon D, Wells F, Wallwork J. Long-term treatment of primary pulmonary hypertension with continuous intravenous epoprostenol (prostacyclin). Lancet 1984;1:1046-7.
16. Shapiro SM, Oudiz RJ, Cao T, et al. Primary pulmonary hypertension: improved long-term effects and survival with continuous intravenous epoprostenol infusion. J Am Coll Cardiol 1997;30:343-9.
17. Jones DA, Benjamin CW, Linseman DA. Activation of thromboxane and prostacyclin receptors elicits opposing effects on vascular smooth muscle cell growth and mitogen-activatcd protein kinase signaling cascades. Mol Pharmacol 1995;48:890-6.